Home / News /
UW IDDRC: Arbaclofen and 16p11.2 Deletion Study
The UW IHDD’s Intellectual and Developmental Disabilities Research Center (IDDRC) invites families, allies, clinicians, and scientists to an upcoming virtual talk by Dr. Paul Wang on November 13, 2025.
Dr. Wang will present preliminary results from the L16HTHOUSE study, a Phase 2 clinical trial investigating the safety, tolerability, and efficacy of arbaclofen in children with 16p11.2 BP4-BP5 deletion (ClinicalTrials.gov ID: NCT04271332).
This event is open to the public and aims to share emerging insights from this important research effort.
- Date: November 13, 2025
- Time: 6–7 PM Eastern (3–4 PM Pacific)
- Location: Zoom
RSVP for the Zoom link.
